Meniere's disease. Labyrinthine hydrops Ménière's syndrome or vertigo
Conditions
Interventions
Intervention 1: Participants who are randomly placed in placebo group, besides having a low salt diet will take the placebo pills (inert ingredient) for 10 days 5 times a day, then 3 times a day for n
Placebo
Treatment - Drugs
Patients who were randomly allocated to the Acyclovir group besides having low salt diet will take the Acyclovir 400 mg pills (Zovirax) for 10 days 5 times a day, then 3 times a day for next 10 days
Participants who are randomly placed in placebo group, besides having a low salt diet will take the placebo pills (inert ingredient) for 10 days 5 times a day, then 3 times a day for next 10 days, and
Sponsors
Vice Chancellor of Research, Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria:1. Patients' willingness to participate in the study 2. Willingness to participate in follow ups 3. Age of 18 or older 4. Having at least 2 vertigos per month each lasting for at least 20 minutes, severely interfering with function 5. Not on medication for at least 3 months before starting the trial. Exclusion Criteria: 1. History of Allergy to Acyclovir or the drugs in the same category 2. Renal insufficiency or having Creatinine more than 1.5 mg/dl 3. Hepatic enzymes more than 3 times normal 4. Hematocrit less than 30% 5. Thrombocytopenia 6. Having a serious uncontrolled illness 7. Pregnant or nursing ladies 8. Using Probenecid 9. Previous surgeries on endolymphatic sac.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Vertigo. Timepoint: Before intervention, 1 month, 3 months and 6 months after the intervention. Method of measurement: Subjective. | — |
Secondary
| Measure | Time frame |
|---|---|
| Aural fullness. Timepoint: Before intervention, 1 month, 3 months and 6 months after the intervention. Method of measurement: Subjective evaluation in a 0(with no symptom) to 4 (very severe) scale.;Incidence of patients experiencing nausea as side effect. Timepoint: Before intervention, 1 month, 3 months and 6 months after the intervention. Method of measurement: Patient's subjective evaluation.;Tinnitus. Timepoint: Before intervention, 1 month, 3 months and 6 months after the intervention. Method of measurement: Subjective evaluation in a 0 (with no symptom) to 4 (very severe) scale.;Change in renal function as a side effect. Timepoint: Before intervention, 1 month, 3 months and 6 months after the intervention. Method of measurement: Renal function test , if history suggestive of that.;Hearing. Timepoint: Before intervention, 1 month, 3 months and 6 months after the intervention. Method of measurement: Audiometry and also subjective evaluation. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Masoud Motesadi
Amiralam Hospital, Tehran University of Medical Sciences
Outcome results
None listed